Clinical and immunological features of metabolic phenotype of osteoarthritis

Forty women with gonarthrosis were included in this study. The main group consisted of 19 patients having osteoarthritis (OA) with metabolic syndrome (MS), the control group consisted of 21 patients with OA but without MS. It was found that metabolic phenotype of gonarthrosis, i.e. OA with concomita...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	V. S. Shirinsky, N. Yu. Kalinovskaya, K. Yu. Filatova, I. V. Shirinsky
Formato:	article
Lenguaje:	RU
Publicado:	SPb RAACI 2020
Materias:	osteoarthritis metabolic syndrome immune system low-grade inflammation cytokines lipids crp Immunologic diseases. Allergy RC581-607
Acceso en línea:	https://doaj.org/article/e0c97b980ba84fc4b42bf96c77a646a7
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:e0c97b980ba84fc4b42bf96c77a646a7
record_format	dspace
spelling	oai:doaj.org-article:e0c97b980ba84fc4b42bf96c77a646a72021-11-18T08:03:49ZClinical and immunological features of metabolic phenotype of osteoarthritis1563-06252313-741X10.15789/1563-0625-CAI-1881https://doaj.org/article/e0c97b980ba84fc4b42bf96c77a646a72020-04-01T00:00:00Zhttps://www.mimmun.ru/mimmun/article/view/1881https://doaj.org/toc/1563-0625https://doaj.org/toc/2313-741XForty women with gonarthrosis were included in this study. The main group consisted of 19 patients having osteoarthritis (OA) with metabolic syndrome (MS), the control group consisted of 21 patients with OA but without MS. It was found that metabolic phenotype of gonarthrosis, i.e. OA with concomitant MS, was different from OA without MS in terms of pain measured with visual analogue scale (VAS) (65 mm in the main group vs 47 mm in control group, р = 0.001) and other OA symptoms in accordance with Knee Osteoarthritis Outcome Scale (KOOS) (43.2 points in the main group vs 76.1 points in the control group, р = 0.001). These main distinguishing features were associated with low quality of life measured with non-specific questionnaire Short Form -36 (SF-36) (30 points in the main group and 40 points in the control) and clinically significant signs of depression, detected with Patient Health Questionnaire-9 (PHQ-9) (12 points in the main group and 7 points in the control group). The metabolic phenotype of gonarthrosis was characterized with laboratory features of low-grade systemic inflammation as evidenced by increased CRP (11.4 mg/ml in the main group vs 3.2 mg/ml in the control group, р = 0.03), IL-6 (2.6 pg/ml in the main group vs 0.7 pg/ml in the control group, р = 0.001), IL-18 (196.6 pg/ml in the main group vs 61.4 pg/ml in the control group, р = 0.001) in the peripheral blood serum, as well as increase in antibodies against Col2 (27.1 ng/ml in the main vs 5.5 ng/ml in the control group, р = 0.01) , and dyslipidaemia — increase in LDL-cholesterol (5.5 mmol/l in the main group vs 5.9 mmol/l in the control group, р = 0.032) and triglycerides (2.026 mmol/l in the main group and 1.36 mmol/l in the control gropu, р = 0.02). In conclusion, MS-associated OA phenotype occurs due to pathogenetic similarities between OA and MS (syntropy) based on systemic low grade inflammation. This OA phenotype is not well studied and needs further research to develop new treatments targeting these two comorbid disorders as a single disease.V. S. ShirinskyN. Yu. KalinovskayaK. Yu. FilatovaI. V. ShirinskySPb RAACIarticleosteoarthritismetabolic syndromeimmune systemlow-grade inflammationcytokineslipidscrpImmunologic diseases. AllergyRC581-607RUMedicinskaâ Immunologiâ, Vol 22, Iss 2, Pp 327-334 (2020)
institution	DOAJ
collection	DOAJ
language	RU
topic	osteoarthritis metabolic syndrome immune system low-grade inflammation cytokines lipids crp Immunologic diseases. Allergy RC581-607
spellingShingle	osteoarthritis metabolic syndrome immune system low-grade inflammation cytokines lipids crp Immunologic diseases. Allergy RC581-607 V. S. Shirinsky N. Yu. Kalinovskaya K. Yu. Filatova I. V. Shirinsky Clinical and immunological features of metabolic phenotype of osteoarthritis
description	Forty women with gonarthrosis were included in this study. The main group consisted of 19 patients having osteoarthritis (OA) with metabolic syndrome (MS), the control group consisted of 21 patients with OA but without MS. It was found that metabolic phenotype of gonarthrosis, i.e. OA with concomitant MS, was different from OA without MS in terms of pain measured with visual analogue scale (VAS) (65 mm in the main group vs 47 mm in control group, р = 0.001) and other OA symptoms in accordance with Knee Osteoarthritis Outcome Scale (KOOS) (43.2 points in the main group vs 76.1 points in the control group, р = 0.001). These main distinguishing features were associated with low quality of life measured with non-specific questionnaire Short Form -36 (SF-36) (30 points in the main group and 40 points in the control) and clinically significant signs of depression, detected with Patient Health Questionnaire-9 (PHQ-9) (12 points in the main group and 7 points in the control group). The metabolic phenotype of gonarthrosis was characterized with laboratory features of low-grade systemic inflammation as evidenced by increased CRP (11.4 mg/ml in the main group vs 3.2 mg/ml in the control group, р = 0.03), IL-6 (2.6 pg/ml in the main group vs 0.7 pg/ml in the control group, р = 0.001), IL-18 (196.6 pg/ml in the main group vs 61.4 pg/ml in the control group, р = 0.001) in the peripheral blood serum, as well as increase in antibodies against Col2 (27.1 ng/ml in the main vs 5.5 ng/ml in the control group, р = 0.01) , and dyslipidaemia — increase in LDL-cholesterol (5.5 mmol/l in the main group vs 5.9 mmol/l in the control group, р = 0.032) and triglycerides (2.026 mmol/l in the main group and 1.36 mmol/l in the control gropu, р = 0.02). In conclusion, MS-associated OA phenotype occurs due to pathogenetic similarities between OA and MS (syntropy) based on systemic low grade inflammation. This OA phenotype is not well studied and needs further research to develop new treatments targeting these two comorbid disorders as a single disease.
format	article
author	V. S. Shirinsky N. Yu. Kalinovskaya K. Yu. Filatova I. V. Shirinsky
author_facet	V. S. Shirinsky N. Yu. Kalinovskaya K. Yu. Filatova I. V. Shirinsky
author_sort	V. S. Shirinsky
title	Clinical and immunological features of metabolic phenotype of osteoarthritis
title_short	Clinical and immunological features of metabolic phenotype of osteoarthritis
title_full	Clinical and immunological features of metabolic phenotype of osteoarthritis
title_fullStr	Clinical and immunological features of metabolic phenotype of osteoarthritis
title_full_unstemmed	Clinical and immunological features of metabolic phenotype of osteoarthritis
title_sort	clinical and immunological features of metabolic phenotype of osteoarthritis
publisher	SPb RAACI
publishDate	2020
url	https://doaj.org/article/e0c97b980ba84fc4b42bf96c77a646a7
work_keys_str_mv	AT vsshirinsky clinicalandimmunologicalfeaturesofmetabolicphenotypeofosteoarthritis AT nyukalinovskaya clinicalandimmunologicalfeaturesofmetabolicphenotypeofosteoarthritis AT kyufilatova clinicalandimmunologicalfeaturesofmetabolicphenotypeofosteoarthritis AT ivshirinsky clinicalandimmunologicalfeaturesofmetabolicphenotypeofosteoarthritis
_version_	1718422321244405760

Clinical and immunological features of metabolic phenotype of osteoarthritis

Ejemplares similares